JMP Securities Downgrades Intra-Cellular Therapies (ITCI) to Market Perform
Tweet
Share
E-mailGet Alerts ITCI Hot Sheet
Price: $131.87 --0%
Rating Summary:
9 Buy, 11 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 2
Rating Summary:
9 Buy, 11 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 2
Join SI Premium – FREE
JMP Securities downgraded Intra-Cellular Therapies (NASDAQ: ITCI) from Market Outperform to Market Perform and removed its price target (prior $55.00).
For an analyst ratings summary and ratings history on Intra-Cellular Therapies click here. For more ratings news on Intra-Cellular Therapies click here.
Shares of Intra-Cellular Therapies closed at $42.35 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- HSBC Downgrades Shriram Finance Ltd (SHFL:IN) to Hold
- ICICI Securities Downgrades LTIMindtree Ltd (LTIM:IN) to Reduce (4)
- ICICI Securities Downgrades Tata Consultancy Services Ltd. (TCS:IN) to Reduce (4)
Create E-mail Alert Related Categories
DowngradesRelated Entities
The Children's Investment Fund (TCI), JMP SecuritiesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
